Literature DB >> 22668781

Activation of subthalamic alpha 2 noradrenergic receptors induces motor deficits as a consequence of neuronal burst firing.

Claire Delaville1, Jonathan Zapata, Laura Cardoit, Abdelhamid Benazzouz.   

Abstract

The subthalamic nucleus (STN) plays a key role in the pathophysiology of Parkinson's disease. This was demonstrated by the fact that STN neurons express more bursts in animal models of the disease and by the ability of STN inactivation to alleviate motor deficits. However, the origin of the bursts and the causal link between STN bursts and motor deficits remain unknown. The present study aimed to investigate the role of noradrenergic receptor modulation on the firing activity of STN neurons and the impact of this modulation on locomotor activity in sham and 6-hydroxydopamine-lesioned rats. Using selective agonists and antagonists of α1- and α2-adrenergic receptors (AR), we show that local infusion of clonidine, an α2-AR agonist, induced a switch from tonic to bursty pattern without changing the firing rate. This change in the pattern was prevented by the local infusion of idazoxan, an α2-AR antagonist. Furthermore, clonidine injection into the STN reduced locomotor activity in sham and 6-hydroxydopamine-lesioned rats. In contrast, local injection of phenylephrine, an α1-AR agonist, increased the firing rate of STN neurons without changing the firing pattern. In parallel, phenylephrine did not change locomotor activity. This is the first evidence showing the implication of α1-ARs in the modulation of firing rate and α2-ARs in the modulation of the firing pattern of STN neurons. Furthermore, our data provide also evidence that activation of the STN α2-ARs plays a key role in the genesis of subthalamic burst activity, which may be at the origin of motor deficits.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22668781     DOI: 10.1016/j.nbd.2012.05.019

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  6 in total

1.  Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.

Authors:  Britahny M Baskin; Bríd Á Nic Dhonnchadha; Linda P Dwoskin; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2017-07-20       Impact factor: 4.530

2.  The α2B-adrenergic receptor is mutant in cortical myoclonus and epilepsy.

Authors:  Maurizio De Fusco; Riccardo Vago; Pasquale Striano; Carlo Di Bonaventura; Federico Zara; Davide Mei; Min Seuk Kim; Shmuel Muallem; Yunjia Chen; Qin Wang; Renzo Guerrini; Giorgio Casari
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

3.  Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson's disease.

Authors:  Kinga Kamińska; Tomasz Lenda; Jolanta Konieczny; Elżbieta Lorenc-Koci
Journal:  Psychopharmacology (Berl)       Date:  2022-09-30       Impact factor: 4.415

4.  Dopaminergic control of the globus pallidus through activation of D2 receptors and its impact on the electrical activity of subthalamic nucleus and substantia nigra reticulata neurons.

Authors:  Omar Mamad; Claire Delaville; Wail Benjelloun; Abdelhamid Benazzouz
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

5.  Identifying the Basal Ganglia network model markers for medication-induced impulsivity in Parkinson's disease patients.

Authors:  Pragathi Priyadharsini Balasubramani; V Srinivasa Chakravarthy; Manal Ali; Balaraman Ravindran; Ahmed A Moustafa
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

6.  Influence of Anesthesia and Clinical Variables on the Firing Rate, Coefficient of Variation and Multi-Unit Activity of the Subthalamic Nucleus in Patients with Parkinson's Disease.

Authors:  Michael J Bos; Ana Maria Alzate Sanchez; Raffaella Bancone; Yasin Temel; Bianca T A de Greef; Anthony R Absalom; Erik D Gommer; Vivianne H J M van Kranen-Mastenbroek; Wolfgang F Buhre; Mark J Roberts; Marcus L F Janssen
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.